Acute Pancreatitis
Conditions
Keywords
Pancreatitis
Brief summary
This will be a phase 2, single-center, unblinded randomized controlled pilot trial of two arms comparing opioid-sparing analgesia to the current Boston Children's Hospital institutional practice which has been reported to predominantly include administration of opioids as a first-line analgesic to pediatric patients who present to the emergency department with a diagnosis of acute pancreatitis (AP). This is a pilot trial for which many outcomes have not previously been studied in the pediatric AP population. The focus of this investigation will be to investigate the magnitude and variability of effect sizes for designing a future multi-center, double-blinded randomized controlled trial.
Detailed description
Acute pancreatitis (AP) is the most common pancreatic disease of childhood with an increasing incidence estimated at 13.2 cases in 100,000 children per year. Given the dearth of pediatric literature, most pediatric providers often rely on diagnostic, prognostic and treatment guidelines that have been derived from adults. This is problematic because adult therapeutic guidelines fail to consider the unique age-related responses and requirements of childhood. Pain management is one of the cornerstones in the treatment of pancreatitis, with abdominal pain being the most common presenting symptom of AP. Currently, there are no data on optimal pain management in pediatric AP. Older guidelines suggest that the use of intravenous patient-controlled analgesia (PCA) is advantageous as it allows the patient to self-administer opioids and strike a balance between analgesia and side effects. This requires cognitive maturity to understand how to use PCA and poses challenges for younger children, particularly infants and toddlers, as well as pediatric patients with developmental delay. It is particularly concerning that greater than 94% of surveyed pediatric practitioners would use morphine or related opioids as a first-line therapy in children with AP especially when there have been no studies examining the benefits/risks of opioid vs non-opioid analgesics or opioid-sparing therapies in pediatric AP. Furthermore, we recently reported a retrospective analysis demonstrating that opioids are prescribed far more frequently either alone or in combination with non-opioids (70%) than non-opioid alternatives alone (30%). Amongst all types of analgesia prescribed to children who presented to the BCH emergency department (ED) with acute pancreatitis, morphine was the most common. Further research in this area is imperative, particularly given the recent opioid epidemic. From a pediatric perspective, it has been demonstrated that adolescents are amongst those at risk for opioid abuse, thus there is an urgent need to determine whether opioids are necessary for the management of pain in this vulnerable population with AP.
Interventions
DRUGKetorolac
Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.
DRUGOpioid
Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
Sponsors
The National Pancreas Foundation
Boston Children's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
This will be a phase 2, single-center, unblinded randomized controlled pilot trial of two arms comparing opioid-sparing analgesia to the current BCH institutional practice which has been reported to predominantly include administration of opioids as a first-line analgesic to pediatric patients who present to the emergency department with a diagnosis of acute pancreatitis.
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
1. Patients who present to the ED and are admitted to BCH with a diagnosis of acute pancreatitis or an acute bout of chronic pancreatitis based on INSPPIRE14 Criteria (Appendix 1) 2. Age ≤21 years 3. Patient weight ≥8 kg
Exclusion criteria
1. Allergy to morphine (and hydromorphone) or aspirin/NSAID 2. History of renal or hepatic insufficiency 3. History of peptic ulceration 4. History of bleeding diathesis 5. Pregnant females 6. Patients who have a documented history of substance abuse disorder or those who use opioids chronically 7. Patients admitted to the Intensive Care Unit (ICU) 8. Patients who received intravenous opioid patient-controlled analgesia (PCA) in transit or during their ED admission.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy: amount of opioid analgesia (mg/kg/hr) from the time of enrollment until discharge home, transfer to the ICU, or initiation of PCA | time of enrollment through study completion (approximately 5 days), or transfer to the ICU or initiation of PCA | The primary endpoint for efficacy is the amount of opioid analgesia (mg/kg/hr) from the time of enrollment until discharge home, transfer to the ICU, or initiation of PCA. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety: number of hours from the time of enrollment until discharge home, transfer to the ICU, or initiation of PCA | time of enrollment through study completion (approximately 5 days), or transfer to the ICU or initiation of PCA | The secondary endpoint for safety is defined as the total number of incident adverse events, grade 2 or higher, from the time of enrollment until discharge home, transfer to the ICU, or initiation of PCA. |
| Length of stay | time of enrollment through study completion (approximately 5 days), or transfer to the ICU or initiation of PCA | The secondary endpoint for length of stay is defined as the number of hours from the time of enrollment until discharge home, transfer to the ICU, or initiation of PCA. |
| Time to initiation of oral or enteral diet | time of enrollment through study completion (approximately 5 days), or transfer to the ICU or initiation of PCA | The secondary endpoint for time to initiation of oral or enteral diet is defined as the number of hours from the time of enrollment until first oral or enteral intake. The number of hours will be expressed to two decimal places to account for fractions of an hour. |
| Predefined Feasibility Outcomes to Assess Trial Success | duration of trial, approximately 1 year from the start of enrollment | The secondary endpoint for feasibility is defined as (1) ≥80% of eligible patients approached for consent during the trial, and (2) ≥20% of eligible patients randomized into the trial. |
| Pain resolution: pain scores | time of enrollment through study completion (approximately 5 days), or transfer to the ICU or initiation of PCA | To compare pain resolution from time of enrollment throughout hospital stay by comparing pain scores in patients receiving opioid-sparing therapies to those receiving standard of care opioid analgesics. |
Countries
United States
Outcome results
None listed